After Combining Assets, Takeda/Millennium Outline Oncology Strategy
This article was originally published in The Pink Sheet Daily
Executive Summary
With 13 oncology molecules in the clinic, R&D priorities include motesanib for lung cancer, an aurora A kinase inhibitor and expansion of Takeda’s prostate cancer expertise.